Europe’s medical devices industry saw a drop of 8.57% in deal activity during June 2021

Europe’s medical devices industry saw a drop of 8.57% in deal activity during June 2021, when compared with the last 12-month average, led by Ally Bridge Group, Cambridge Innovation Capital, Chimera Partners, GE Healthcare, LGT Impact Ventures, Lightrock, PFM Health Sciences, RPMI Railpen, SoftBank Vision Fund II, Tencent Holdings and Watrium’s $600m venture financing of CMR Surgical, according to GlobalData’s deals database.

 

A total of 32 medical devices industry deals worth $1.6bn were announced for the region in June 2021, against the 12-month average of 35 deals.

Of all the deal types, venture financing saw most activity in June 2021 with 17 transactions, representing a 53.1% share for the region.

In second place was M&A with eight deals, followed by private equity deals with seven transactions, respectively capturing a 25% and 21.9% share of the overall deal activity for the month.

In terms of value of deals, venture financing was the leading category in Europe’s medical devices industry with $988.43m, while M&A and private equity deals totalled $379.63m and $255.41m, respectively.

Europe medical devices industry deals in June 2021: Top deals

The top five medical devices deals accounted for 88.5% of the overall value during June 2021.

The combined value of the top five medical devices deals stood at $1.44bn, against the overall value of $1.6bn recorded for the month.

The top five medical devices industry deals of June 2021 tracked by GlobalData were:

1) Ally Bridge Group, Cambridge Innovation Capital, Chimera Partners, GE Healthcare, LGT Impact Ventures, Lightrock, PFM Health Sciences, RPMI Railpen, SoftBank Vision Fund II, Tencent Holdings and Watrium’s $600m venture financing of CMR Surgical

2) The $317.38m acquisition deal with HalioDx by Veracyte

3) BlackRock, btov Partners, Eldridge Industries, Glenview Capital Management, Millennium Management, Monashee Investment Management, Novo Holdings, Orlando Health, Puhua Capital, Sands Capital Management, Segulah, Seroba Life Sciences Management and Wellington Partners’ $245m venture financing of Quanta Dialysis Technologies

4) The $222.69m private equity deal with Elos Medtech by EM Intressenter and TA Associates Management

5) Oxford Instruments’ acquisition of WITec Wissenschaftliche Instrumente und Technologie for $50.92m.